Research Papers:

This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.

COX-2 expression in ovarian cancer: an updated meta-analysis

Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao and Yan Jin _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:88152-88162. https://doi.org/10.18632/oncotarget.21538

Metrics: PDF 1476 views  |   HTML 3675 views  |   ?  


Haiming Sun1,2, Xuelong Zhang1, Donglin Sun1, Xueyuan Jia1, Lidan Xu1, Yuandong Qiao1 and Yan Jin1

1Laboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China

2National Human Genome Research Institute, National Institutes of Health, Baltimore, MD 21224, USA

Correspondence to:

Yan Jin, email: [email protected].

Keywords: COX-2, ovarian cancer, meta-analysis, prognosis

Received: February 24, 2017     Accepted: July 12, 2017     Published: October 04, 2017


The prognostic role of COX-2 expression in ovarian cancer patients has been studied for years, while results remain controversial. Thus we performed a meta-analysis to evaluate the prognostic impact of COX-2 expression on survival of ovarian cancer patients. The databases PubMed, Embase and CNKI were searched. Summary hazard ratio (HR) and 95% confidence intervals (CIs) were calculated to analyze the correlations between COX-2 expression and overall survival (OS), and disease-free survival (DFS). A total of 1,867 patients from 18 studies were enrolled in the final analysis. The results showed that patients with higher COX-2 expression had a poor OS (HR: 1.48; 95% CI: 1.19-1.85) and DFS (HR: 1.81, 95% CI: 1.28-2.55). Subgroup analysis showed that there had significant associations between COX-2 expression and survival rate in most of the subgroups. Furthermore, there were significant associations between COX-2 expression and several clinical parameters such as FIGO stage, histological type and age. These results showed the patients with higher COX-2 expression had a significantly poorer survival rate, COX-2 expression had the potential to be a prognostic marker of ovarian cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21538